Inbeeo, a consultancy specializing in market access and pricing strategies for innovative drugs and medical devices, is joining Enosium Life Science, an integrated life sciences services group founded by Dr. Antoine Amer.
Founded in 2018 by Hervé Lilliu, Inbeeo quickly distinguished itself through its unique expertise in delivering tailor-made solutions to address the toughest market access challenges faced by pharmaceutical companies and medical technology suppliers in European, American, and Asian markets.
This integration into a multi-specialist group offers Inbeeo’s clients a unique opportunity to benefit from high-value-added services across the entire value chain of healthcare products.
Enosium Life Science, through its three strategic acquisitions—Inbeeo, Vyoo Agency (specializing in health economics), and Epione (a major player in scientific communication)—is now positioning itself as a key player in Europe, offering a comprehensive and integrated range of services from clinical research to the commercialization of healthcare products.
Hervé Lilliu, Founder and CEO of Inbeeo, said: “We are extremely proud to join the Enosium Life Science group. This new partnership is a fantastic opportunity for Inbeeo to continue its growth and access additional expertise to keep innovating in market access strategies. Together with Enosium Life Science, we share the same vision: making medical innovations more accessible to patients.”
“We are delighted to welcome Hervé Lilliu and his team of experts to Enosium Life Science. Inbeeo brings valuable expertise in market access strategies, which will complement and strengthen our service offerings alongside Vyoo Agency and Epione. Together, we are building a leading group in Europe, capable of supporting our clients at all key stages when launching their healthcare product,” concludes Antoine Amer, Founder and CEO of Enosium Life Science.
